YOLFTbeta
LAUNXP Biomedical Co., Ltd

LAUNXP Biomedical Co., Ltd

6876 · TWO · Healthcare / Biotechnology

14.00TWD-0.05 (-0.36%)

Price History

Full chart

Market Stats

Previous Close14.05
Open14.05
Day Range13.50 – 14.05
52-Week Range9.09 – 25.45
Volume76.78K
Market Cap1.12B
P/E (TTM)0.00
Forward P/E0.00
EPS-7.17
Dividend Yield0.00%
50-Day Avg13.71
200-Day Avg18.65

About

LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients. It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect treatment. The company was founded in 2015 and is based in Taichung, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Chiu-Heng Chen
  • HeadquartersB1 Room, No. 51, Section 2, Taichung, Taiwan, 408, Taiwan
  • Websitehttps://www.launxp.com

Leadership

  • Dr. Chiu-Heng ChenPresident & Director
  • Aileen HsuChief Financial Officer
  • Bobo ChenChief Technology Officer

Financials

Income Statement

Currency: TWD2021-12-312022-12-312023-12-312024-12-31
Total Revenue0011.00K2.48M
Growth (%)---+22481.82%
Cost of Revenue000199.00K
Gross Profit0011.00K2.29M
Gross Margin--100.00%91.99%
Operating Expense34.83M43.62M81.06M84.59M
Operating Income-34.83M-43.62M-81.05M-82.30M
Operating Margin---736809.09%-3313.37%
EBITDA--41.07M-78.37M-79.65M
EBITDA Margin---712436.36%-3206.44%
Net Income-34.75M-43.61M-80.95M-82.59M
Net Income Margin---735900.00%-3325.08%
R&D15.14M19.72M43.68M37.65M
R&D as % of Total Revenue--397054.55%1515.62%
Interest Expense60.00K195.00K167.00K42.00K
Interest Expense % of Total Revenue--1518.18%1.69%

Balance Sheet

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets73.88M32.44M206.49M123.91M-
Total Liabilities8.65M10.23M23.19M15.05M-
Total Equity65.23M22.21M183.30M108.86M-
Cash34.12M15.20M179.73M98.37M-

Cash Flow

Currency: TWD2021-12-312022-12-312023-12-312024-12-31
Operating Cash Flow-28.99M-44.21M-59.14M-76.66M
Capital Expenditure4.24M804.00K3.31M316.00K
Free Cash Flow-33.24M-45.02M-62.45M-76.97M
FCF to OCF114.64%101.82%105.61%100.41%

Key Statistics & Ratios

Market Cap1.12B
Enterprise Value764.68M
Trailing P/E0.00
Forward P/E0.00
Price / Sales1688.84
Price / Book3.29
EPS-7.17
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity0.00%
Return on Assets0.00%
Shares Outstanding70.53M
Shares Float0
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%